Neuronetics Appoints Nir Naor as Chief Financial Officer
Neuronetics, Inc. (NASDAQ: STIM), a neurostimulation medical device company, appointed Nir Naor as CFO on September 28, 2026. Naor brings prior CFO experience at life sciences firms, with deep expertise in ASC 606 revenue recognition, clinical trial cost capitalization, and SEC periodic reporting.
51CFO view：This CFO appointment underscores intensifying SEC focus on ASC 606 implementation and R&D expense treatment in medtech. For Chinese IPO candidates, the CFO must design jurisdiction-aware revenue allocation models and operate SEC filing tools (e.g., Workiva) — not just manage audits.
Neuronetics, Inc. (NASDAQ: STIM), a neurostimulation medical device company, appointed Nir Naor as CFO on September 28, 2026. Naor brings prior CFO experience at life sciences firms, with deep expertise in ASC 606 revenue recognition, clinical trial cost capitalization, and SEC periodic reporting.
Source：Google News · CFO 任命
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
How is a US-listed CFO paid?
Base, equity incentive and listing-milestone bonus: structure and ranges.
Read →
Who owns SEC reporting and US GAAP?
Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments.
Read →
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →